Schonfeld Strategic Advisors’s European Biotech Acquisition Corp. Class A Ordinary Shares EBAC Stock Holding History

Schonfeld Strategic Advisors’s Portfolio EBAC Stock Details EBAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-14,237	Closed	-$144K	–	2947
2022 Q4	$144K	Hold	14,237	–	–	﹤0.01%	2091
2022 Q3	$141K	Hold	14,237	–	–	﹤0.01%	2465
2022 Q2	$139K	Buy	14,237 +345	+2%	+$3.38K	﹤0.01%	2048
2022 Q1	$136K	Buy	+13,892	New	+$135K	﹤0.01%	2138

Schonfeld Strategic Advisors's EBAC Position: Q1 2023 in Review

Schonfeld Strategic Advisors sold out of European Biotech Acquisition Corp. Class A Ordinary Shares (EBAC) in Q1 2023, closing a stake of 14,237 shares — an estimated $144K sold.

Schonfeld Strategic Advisors first reported a position in EBAC in Q1 2022 and held it in 4 quarters. The position peaked at $144K in Q4 2022. 0 funds tracked by Wall St. Rank hold EBAC as of Q1 2023.

Schonfeld Strategic Advisors reported no remaining European Biotech Acquisition Corp. Class A Ordinary Shares position as of Q1 2023 after selling out during the quarter.
Schonfeld Strategic Advisors sold 14,237 European Biotech Acquisition Corp. Class A Ordinary Shares shares in Q1 2023, an estimated $144K.
Schonfeld Strategic Advisors first reported a position in European Biotech Acquisition Corp. Class A Ordinary Shares in Q1 2022 and held it in 4 quarters.
Schonfeld Strategic Advisors's European Biotech Acquisition Corp. Class A Ordinary Shares position peaked at $144K in Q4 2022.
0 funds tracked by Wall St. Rank held European Biotech Acquisition Corp. Class A Ordinary Shares as of Q1 2023.

Based on Schonfeld Strategic Advisors's 13F filing for Q1 2023, filed 15 May 2023.